Comparative Pharmacology
Head-to-head clinical analysis: METHYLERGONOVINE MALEATE versus MIGRANAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHYLERGONOVINE MALEATE versus MIGRANAL.
METHYLERGONOVINE MALEATE vs MIGRANAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ergot alkaloid; partial agonist/antagonist at alpha-adrenergic, serotonin (5-HT2), and dopamine receptors; directly stimulates uterine smooth muscle contractions.
MIGRANAL (dihydroergotamine mesylate) is an ergot alkaloid with agonist activity at serotonin 5-HT1D and 5-HT1B receptors, leading to vasoconstriction of cranial blood vessels and inhibition of trigeminal nerve transmission, thereby aborting migraine attacks.
0.2 mg intramuscularly or intravenously once, may repeat as needed every 2-4 hours for a maximum of 5 doses.
1 mg intramuscularly at onset of migraine headache; may repeat after 1 hour if needed. Maximum: 2 mg per day and 4 mg per week.
None Documented
None Documented
Biphasic: initial (alpha) ~10-30 min; terminal (beta) ~2-3 hours in normal subjects; prolonged to ~6-12 hours in hepatic impairment or pregnancy
Terminal elimination half-life ranges from 7 to 10 hours (mean 8.5 hours). Prolonged in renal impairment.
Renal (approximately 60-80% as metabolites, <1% unchanged); biliary/fecal (minor route, approximately 20-30%)
Primarily hepatic metabolism followed by renal excretion. Approximately 10% excreted unchanged in urine; fecal excretion accounts for <1%.
Category D/X
Category C
Ergot Alkaloid
Ergot Alkaloid